Maravai LifeSciences Target of Unusually Large Options Trading (NASDAQ:MRVI)

Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) was the recipient of unusually large options trading activity on Wednesday. Investors acquired 1,002 put options on the stock. This is an increase of 1,791% compared to the average volume of 53 put options.

Institutional Trading of Maravai LifeSciences

Institutional investors have recently modified their holdings of the stock. Performa Ltd US LLC grew its position in shares of Maravai LifeSciences by 614.3% in the 4th quarter. Performa Ltd US LLC now owns 5,000 shares of the company’s stock valued at $27,000 after buying an additional 4,300 shares during the last quarter. Teacher Retirement System of Texas purchased a new position in shares of Maravai LifeSciences during the first quarter worth about $37,000. FNY Investment Advisers LLC increased its position in shares of Maravai LifeSciences by 600.0% during the fourth quarter. FNY Investment Advisers LLC now owns 7,000 shares of the company’s stock worth $38,000 after purchasing an additional 6,000 shares in the last quarter. Pekin Hardy Strauss Inc. acquired a new stake in shares of Maravai LifeSciences during the first quarter worth about $55,000. Finally, Farther Finance Advisors LLC lifted its holdings in shares of Maravai LifeSciences by 3,541.4% in the 4th quarter. Farther Finance Advisors LLC now owns 10,196 shares of the company’s stock valued at $56,000 after purchasing an additional 9,916 shares during the last quarter. Hedge funds and other institutional investors own 50.25% of the company’s stock.

Maravai LifeSciences Price Performance

MRVI stock opened at $2.03 on Friday. The business has a 50 day moving average price of $2.29 and a 200 day moving average price of $4.49. The company has a quick ratio of 9.94, a current ratio of 10.74 and a debt-to-equity ratio of 0.89. The stock has a market cap of $516.30 million, a price-to-earnings ratio of -1.24 and a beta of 0.18. Maravai LifeSciences has a fifty-two week low of $1.67 and a fifty-two week high of $11.56.

Wall Street Analysts Forecast Growth

Several research firms have commented on MRVI. Stifel Nicolaus set a $5.00 price target on shares of Maravai LifeSciences in a research note on Friday, March 21st. Bank of America lowered their target price on Maravai LifeSciences from $9.00 to $8.00 and set a “buy” rating for the company in a research note on Monday, March 3rd. Morgan Stanley reduced their price target on Maravai LifeSciences from $7.00 to $5.00 and set an “equal weight” rating on the stock in a research report on Tuesday, March 25th. Robert W. Baird downgraded Maravai LifeSciences from an “outperform” rating to a “neutral” rating and lowered their price objective for the stock from $9.00 to $3.00 in a research report on Wednesday, February 26th. Finally, Baird R W lowered shares of Maravai LifeSciences from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, February 26th. One investment analyst has rated the stock with a sell rating, seven have given a hold rating and three have issued a buy rating to the company. According to data from MarketBeat.com, Maravai LifeSciences presently has a consensus rating of “Hold” and an average target price of $6.34.

Maravai LifeSciences Company Profile

Maravai LifeSciences Holdings, Inc, a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company’s products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species.